Influence of antiviral therapy on survival of patients with hepatitis B-associated hepatocellular carcinoma undergoing transarterial chemoembolization
Purpose: To examine the prognostic value of antiviral therapy among hepatocellular carcinoma (HCC) patients undergoing transarterial chemoembolization (TACE).
Method: A total of 356 patients with HCC undergoing TACE were recruited for the purpose of current study. All the patients were categorized into two groups; antiviral (n = 132) and non-antiviral group (n = 224). All the clinical and laboratory parameters were noted at baseline. Patients were then followed up for five years. The mortality rates in two groups were evaluated with Kaplan-Meier estimate.
Results: The average age of the participants was 51.2 ± 6.17 years. A majority (329; 92.4 %) of the patients were male while females constituted only 7.6 %. During five years follow-up period, a total of 274 (76.9 %) died, with 89 patients belonging to the antiviral group while the remaining 185 patients were in the non-antiviral group. Mortality rate significantly differed between the antiviral and non-antiviral groups (67.4 % versus 82.5 %, p = 0.028). The results of Cox regression demonstrated that being a smoker, low serum albumin, local ablation and resection decreased overall survival while female gender, antiviral therapy, and early tumor site-node-metastatis (TNM) staging increased overall survival.
Conclusion: Antiviral therapy for underlying hepatitis B in HCC patients undergoing TACE prolongs overall survival and prevents or delays reactivation of tumor.
Keywords: Cancer, Chemoembolization, Hepatitis, Hepatocellular carcinoma, Transarterial chemoembolization (TACE)
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.